Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
The latest news, research, and perspectives in chronic lymphocytic leukemia (CLL). The most common leukemia subtype among adults, CLL occurs when an acquired mutation causes bone marrow to produce abnormal lymphocytes. As these leukemic cells proliferate, the disorder is associated with lymphadenopathy, splenomegaly, and cytopenias.
Advertisement
Blood Cancer TalksChronic Lymphocytic Leukemia | January 31, 2025
David Russler-Germain, MD, PhD, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and CLL.
Listen Now
Andrew MorenoT-Cell Lymphoma | January 30, 2025
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
Andrew MorenoAggressive B-Cell Lymphoma | January 29, 2025
The single-slide test helps clinicians differentiate more than 60 subtypes of these diseases from normal immune response.
Melissa BadamoChronic Lymphocytic Leukemia | January 29, 2025
The IPS-E, CR0, AIPS-E, CLL-IPI, and Barcelona-Brno risk scores can predict time to first treatment in CLL patients.
Jeff P. Sharman, MDChronic Lymphocytic Leukemia | January 25, 2025
Jeff P. Sharman, MD, discusses pivotal findings from the phase III BRUIN CLL-321 trial.
Jeff P. Sharman, MDChronic Lymphocytic Leukemia | January 24, 2025
Jeff P. Sharman, MD, explores unmet needs, prognosis, and novel treatments like pirtobrutinib in CLL.
Advertisement
Melissa BadamoAcute Lymphoblastic Leukemia | January 27, 2025
The US cancer mortality rate has declined by 34%, but the incidence of leukemia and other malignancies is increasing.
Nichole TuckerChronic Lymphocytic Leukemia | January 14, 2025
Extended follow-up was conducted for 652 patients with relapsed or refractory CLL or SLL in the ALPINE study.
Andrew MorenoChronic Lymphocytic Leukemia | January 10, 2025
PFS and safety findings continued trends seen in prior results at 26.2 months and 43.7 months of median follow-up.
Andrew MorenoAcute Lymphoblastic Leukemia | January 10, 2025
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
Melissa BadamoChronic Lymphocytic Leukemia | January 3, 2025
The research projects aim to improve patient quality of life, address treatment disparities, and increase access to care.
Melissa BadamoChronic Lymphocytic Leukemia | December 18, 2024
First-line, fixed-duration ibrutinib plus venetoclax provides durable PFS and OS for patients with CLL.
Melissa BadamoChronic Lymphocytic Leukemia | December 18, 2024
Venetoclax plus obinutuzumab demonstrates superior safety and efficacy compared with FCR and BR in untreated CLL.
Melissa BadamoChronic Lymphocytic Leukemia | December 18, 2024
Fewer patients in the acalabrutinib group experienced treatment-emergent cardiovascular medical events after BTKi initiation.
Nichole TuckerChronic Lymphocytic Leukemia | December 17, 2024
Results observed in the phase 3 AMPLIFY provide evidence for the all-oral approach to CLL treatment.
Nichole TuckerChronic Lymphocytic Leukemia | December 17, 2024
Real-world data and clinical trial data may support less TLS monitoring in patients with CLL who receive venetoclax.
Nichole TuckerChronic Lymphocytic Leukemia | December 17, 2024
In addition to continued efficacy, zanubrutinib was well tolerated by patients with treatment-naive CLL and SLL.
Nichole TuckerChronic Lymphocytic Leukemia | December 12, 2024
CTX112, a next-generation allogeneic CRISPR-Cas9–engineered showing encouraging results in B-cell malignancies.
Nichole TuckerChronic Lymphocytic Leukemia | January 16, 2025
Results from the TRANSCEND CLL 004 show continued benefit of lisocabtagene maraleucel for R/R CLL treatment.
Julie GouldMeeting News | December 6, 2024
A study stresses psychological support as an essential component of comprehensive cancer care.
Advertisement
Advertisement